Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Biperiden (ausschl. Wirkstärke 4mg), ATC N04AA02 für die Zeit 01.09.26 - 31.08.28 (zzgl. V.-Option 1x12 Mon)

TENDER DESCRIPTION

DAK-Gesundheit assumes that this procedure does not fall within the scope of cartel procurement law due to the absence of a selection decision and thus the non-discriminatory access possibility for all pharmaceutical companies. It ends automatically regardless upon the entry into force of the exclusive contract for the active substance Biperiden (exclusively strength 4mg), ATC N04AA02, following a formal procurement procedure according to the regulations of Part 4 of the GWB with one or more contracting partners. To do justice to the diversity of potential contracting partners within the framework of the approval model, every pharmaceutical company is enabled to conclude a framework contract at any time during the contract term and under the same conditions. The necessary contractual documents are available for download via the online portal www.dtvp.de/center at the link specified under 5.1.11. The prerequisites for conclusion or later accession to the contracts first coming into force on 01.09.2026 are the full and timely submission of the following documents (available for download at the link specified under 5.1.11) to the following department at DAK-Gesundheit: 1. Letter of…

TENDER BRIEF

TENDER DOCUMENTS